Stephen Salloway
Neurology · Providence, RINPI 1891701116
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $240,196 of the $329,256 with a category attached, or 73.0%. 24 manufacturers reported payments, led by Lilly USA, LLC at 30.0% of the total. 2025 is the largest year on record at $91,000, 4.2 times the $21,554 reported in 2019. Among neurology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $1317.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$99K
- Eli Lilly$41K
- Novo Nordisk$35K
- Biogen$34K
- F. Hoffmann-la Roche AG$21K
- Eisai Inc.$20K
- plus $79K from 18 others
Across 399 payments — averaging $39,585 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$6.9M
- Eisai Inc.$3.1M
- Eli Lilly$2.9M
- Genentech, Inc.$1.4M
- Novartis$1.3M
- Janssen Research & Development, LLC$102K
- plus $81K from 3 others
What the payments were for
- Consulting fees$240,19673%
- Speaking & faculty fees$26,7358%
- Travel & lodging$58,15318%
- Food & beverage$4,1731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 45 | $98,661 |
| Eli Lilly | 54 | $41,403 |
| Novo Nordisk | 24 | $34,653 |
| Biogen | 28 | $34,054 |
| F. Hoffmann-la Roche AG | 18 | $21,433 |
| Eisai Inc. | 19 | $20,267 |
| Merck | 10 | $11,677 |
| Avid Radiopharmaceuticals, Inc. | 5 | $8,883 |
| Janssen Global Services, LLC | 10 | $6,932 |
| Genentech, Inc. | 3 | $6,420 |
| E.r. Squibb & Sons, L.L.C. | 4 | $6,244 |
| Roche Products Limited | 6 | $5,827 |
| Amgen | 5 | $5,577 |
| Genentech USA, Inc. | 4 | $5,405 |
| Alnylam Pharmaceuticals Inc. | 1 | $4,050 |
| AbbVie | 1 | $3,600 |
| UCB SA | 5 | $3,244 |
| Janssen Research & Development, LLC | 1 | $2,800 |
| Roche Diagnostics International Ltd | 1 | $2,250 |
| Corium, LLC | 1 | $2,240 |
| Novo Nordisk AS | 2 | $1,860 |
| GE HealthCare | 1 | $1,250 |
| Fujirebio Diagnostics, Incorporated | 1 | $500 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$329,256 in reported general payments places this provider in the 95th percentile of 86 neurology providers in Rhode Island.
Other neurology in Providence
- Syed RizviProvidence$160K
- John EastonProvidence$112K
- Saima ChaudhryProvidence$90K
- Monica DhakarProvidence$45K
- Jeffrey WishikProvidence$34K
- Prathana PrakashProvidence$31K
- Karen FurieProvidence$29K
- Chuang WuProvidence$14K
- Emily WeisbachProvidence$11K
- Shawn TsekhanProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.